PR91734

PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale

RAUBLING, Germany and LYON, France, Sept. 16, 2021 /PRNewswire-=KYODO JBN/ --

PharmaZell, the German producer of highly resilient and specialty APIs, and

France-based Novasep, a leading CDMO focused on complex small molecules and

ADCs have entered into exclusive negotiations to create a leading European

platform in the attractive API manufacturing and CDMO space with a

complementary set of differentiated technologies and highly diversified base of

blue-chip pharma and biotech customers.  

Novasep is a leading CDMO player developing and manufacturing complex small

molecules predominantly for pharma and biotech customers. The company leverages

a wide range of differentiated technologies including high energy and cryogenic

chemistries and industrial scale chromatography. It is a world leader in ADC

and HPAPI, fast-growing targeted cancer therapy segments.

Novasep's capabilities are highly complementary to PharmaZell's expertise in

the manufacturing of complex APIs requiring special handling procedures or

technologies. Combining the two businesses would create a leading, highly

diversified, and highly differentiated API manufacturing and CDMO platform. The

combined business would be able to draw from a comprehensive and broad

technology suite for complex molecules and a global production footprint to

support pharma and biotech customers over the complete lifecycle of a drug. The

combined business would generate nearly €500m of revenues and employ close to

2,000 employees across seven production and R&D sites in Europe (Germany,

France and Italy), two sites in India and one in the US.

The proposed transaction would be backed by PharmaZell's current majority

shareholder Bridgepoint. Bridgepoint Group PLC is the world's leading quoted

private assets growth investor focused on the middle-market with €27 billion

AUM and a local presence in the US, Europe and China.

The proposed acquisition remains subject to the fulfilment of customary

conditions precedent for this type of transaction including the information and

consultation of works councils and other regulatory approvals.

The Press release is available in pdf.

Photo - https://mma.prnewswire.com/media/1628012/Novasep_PharmaZell.jpg  

Logo -

https://mma.prnewswire.com/media/1628011/Novasep_Passion_Smart_Processes_Logo.jpg

PDF - https://mma.prnewswire.com/media/1628027/PharmaZell_Novasep_ENG.pdf

Contact details:

press@novasep.com

SOURCE: Novasep